lactic acid has been researched along with Leishmaniasis, American in 9 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We found that MMWC was toxic for two parasite forms." | 1.39 | In vitro analysis regarding the safety of components used in a film-based therapeutic system loaded with meglumine antimoniate and its activity toward Leishmania major experimental infections: a preliminary study. ( Barbosa, H; Delgado, G; Gutiérrez, J; Pinzón, J; Vallejo, B, 2013) |
| " For this, AMB nanoencapsulated in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles (Nano-D-AMB) has been developed, and its efficacy was evaluated in the treatment of experimental cutaneous leishmaniasis in C57BL/6 mice, to test if our nano-drug delivery system could favor the reduction of the dose frequency required to achieve the same therapeutic level of free D-AMB, and so, an extended dosing interval." | 1.39 | Leishmanicidal activity of amphotericin B encapsulated in PLGA-DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice. ( Báo, SN; Cintra e Silva, Dde O; de Carvalho, RF; de Souza Filho, J; Lacava, ZG; Martins, OP; Miranda-Vilela, AL; Ribeiro, IF; Sampaio, RN; Tedesco, AC, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sousa-Batista, AJ | 1 |
| Arruda-Costa, N | 1 |
| Rossi-Bergmann, B | 1 |
| Ré, MI | 1 |
| Noormehr, H | 1 |
| Zavaran Hosseini, A | 1 |
| Soudi, S | 1 |
| Beyzay, F | 1 |
| Gutiérrez, J | 1 |
| Vallejo, B | 1 |
| Barbosa, H | 1 |
| Pinzón, J | 1 |
| Delgado, G | 1 |
| Navaei, A | 1 |
| Rasoolian, M | 1 |
| Momeni, A | 1 |
| Emami, S | 1 |
| Rafienia, M | 1 |
| de Carvalho, RF | 1 |
| Ribeiro, IF | 1 |
| Miranda-Vilela, AL | 1 |
| de Souza Filho, J | 1 |
| Martins, OP | 1 |
| Cintra e Silva, Dde O | 1 |
| Tedesco, AC | 1 |
| Lacava, ZG | 1 |
| Báo, SN | 1 |
| Sampaio, RN | 1 |
| Santos, DM | 1 |
| Carneiro, MW | 1 |
| de Moura, TR | 1 |
| Fukutani, K | 1 |
| Clarencio, J | 1 |
| Soto, M | 1 |
| Espuelas, S | 1 |
| Brodskyn, C | 1 |
| Barral, A | 1 |
| Barral-Netto, M | 1 |
| de Oliveira, CI | 1 |
| Pinto, MC | 1 |
| Bray, DP | 1 |
| Eiras, AE | 1 |
| Carvalheira, HP | 1 |
| Puertas, CP | 1 |
| SILVESTRI, U | 1 |
| Piñero, J | 1 |
| Temporal, RM | 1 |
| Silva-Gonçalves, AJ | 1 |
| Jiménez, IA | 1 |
| Bazzocchi, IL | 1 |
| Oliva, A | 1 |
| Perera, A | 1 |
| Leon, LL | 1 |
| Valladares, B | 1 |
9 other studies available for lactic acid and Leishmaniasis, American
| Article | Year |
|---|---|
Improved drug loading via spray drying of a chalcone implant for local treatment of cutaneous leishmaniasis.
Topics: Chalcones; Drug Carriers; Drug Compounding; Lactic Acid; Leishmaniasis, Cutaneous; Microspheres; Par | 2018 |
Enhancement of Th1 immune response against Leishmania cysteine peptidase A, B by PLGA nanoparticle.
Topics: Adjuvants, Immunologic; Animals; Cysteine Proteases; Female; Interferon-gamma; Interleukin-4; Lactic | 2018 |
In vitro analysis regarding the safety of components used in a film-based therapeutic system loaded with meglumine antimoniate and its activity toward Leishmania major experimental infections: a preliminary study.
Topics: Antiprotozoal Agents; Cell Line; Cell Survival; Chitosan; Cicatrix; Drug Carriers; Excipients; Fibro | 2013 |
Double-walled microspheres loaded with meglumine antimoniate: preparation, characterization and in vitro release study.
Topics: Antiprotozoal Agents; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Drug Carriers; | 2014 |
Leishmanicidal activity of amphotericin B encapsulated in PLGA-DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Biological Availability; Drug Delivery Systems; Drug | 2013 |
Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11.
Topics: Animals; Antibodies, Protozoan; Antigens, Protozoan; Cytokines; Drug Delivery Systems; Female; Immun | 2012 |
Attraction of the cutaneous leishmaniasis vector Nyssomyia neivai (Diptera: Psychodidae) to host odour components in a wind tunnel.
Topics: Animals; Behavior, Animal; Chemotactic Factors; Disease Vectors; Entomology; Female; Lactic Acid; Le | 2012 |
[Use of lactate of 2 ethoxy-6,9-diaminoacridine (rivanol) in cutaneous leishmaniasis].
Topics: Acridines; Coloring Agents; Ethacridine; Lactates; Lactic Acid; Leishmaniasis; Leishmaniasis, Cutane | 1951 |
New administration model of trans-chalcone biodegradable polymers for the treatment of experimental leishmaniasis.
Topics: Absorbable Implants; Animals; Antiprotozoal Agents; Chalcone; Drug Therapy, Combination; Lactic Acid | 2006 |